共 50 条
- [1] Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancerBREAST CANCER RESEARCH, 2013, 15 (05)Dent, Rebecca A.Lindeman, Geoffrey J.Clemons, MarkWildiers, HansChan, ArleneMcCarthy, Nicole J.Singer, Christian F.Lowe, Elizabeth S.Watkins, Claire L.Carmichael, James
- [2] Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Dent, R. A.Lindeman, G. J.Clemons, M.Wildiers, H.Chan, A.McCarthy, N. J.Singer, C. F.Lowe, E. S.Kemsley, K.Carmichael, J.
- [3] Combination treatment with aromatase inhibitor and capecitabine as first- or second-line treatment in metastatic breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Alvarado Miranda, AlbertoLimon, JesusLara Medina, FernandoArce, ClaudiaWolfgang Zinser, JuanBargallo Rocha, EnriqueMayte Villarreal-Garza, Cynthia
- [4] Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290)CANCER RESEARCH, 2020, 80 (04)Schmid, PeterCortes, JavierRobson, MarkIwata, HirojiHegg, RobertoVerma, SunilNechaeva, MarinaXu, BingheHaddad, VincentImedio, Esteban RodrigoSchiavon, GaiaFoxley, AndrewPark, Yeon Hee
- [5] A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Schmid, PeterCortes, JavierRobson, Mark E.Iwata, HirojiHegg, RobertoNechaeva, MarinaXu, BingheVerma, SunilHaddad, VincentImedio, Esteban RodrigoSchiavon, GaiaFoxley, AndrewPark, Yeon Hee
- [6] A phase Ill randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)CANCER RESEARCH, 2016, 76Emens, L.Adams, S.Loi, S.Schmid, P.Schneeweiss, A.Rugo, H.Chui, S.Winer, E.
- [7] Uracil plus tegafur in a single capsule with oral leucovorin in combination with paclitaxel: A phase I/II trial as second-line treatment of patients with metastatic breastSEMINARS IN ONCOLOGY, 1999, 26 (06) : 12 - 12Klaassen, UHilger, RHenry, JBenner, SHarstrick, ASeeber, S
- [8] Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer TrialJAMA ONCOLOGY, 2022, 8 (12) : 1802 - 1808Loap, PierreLoirat, DelphineBerger, FrederiqueRodrigues, ManuelBazire, LouisPierga, Jean-YvesVincent-Salomon, AnneLaki, FatimaBoudali, LatifaRaizonville, LaurenceMosseri, VeroniqueJochem, AnneEeckhoutte, AlexandreDiallo, MamadouStern, Marc-HenriFourquet, AlainKirova, Youlia
- [9] Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancerBREAST CANCER RESEARCH, 2019, 21 (01)Lee, Jin SunYost, Susan E.Blanchard, SuzetteSchmolze, DanielYin, Hongwei HollyPillai, RajuRobinson, KimTang, AileenMartinez, NormaPortnow, JanaWen, WeiYim, John H.Brauer, Heather AnnRen, YuqiLuu, ThehangMortimer, JoanneYuan, Yuan
- [10] Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancerBreast Cancer Research, 21Jin Sun LeeSusan E. YostSuzette BlanchardDaniel SchmolzeHongwei Holly YinRaju PillaiKim RobinsonAileen TangNorma MartinezJana PortnowWei WenJohn H. YimHeather Ann BrauerYuqi RenThehang LuuJoanne MortimerYuan Yuan